Who We Are

ImmunoGenesis is an immuno-oncology biopharmaceutical company re-envisioning “cold” tumor treatment. Our deliberate drug development strategy is based in the pathology of cold tumors. We are crafting sophisticated, science-driven immune therapies to transform cold tumors into hot tumors by targeting key mechanisms of immune resistance.

Millions without effective treatments

The foundation of modern immuno-oncology treatment is PD-1 and PD-L1 inhibition. And for patients with “hot” tumors (those that are “T-cell inflamed,” meaning they contain many T cells), PD-1 and PD-L1 inhibition offer moderate to high frequency of response and chance for a cure.

Unmet need

Unfortunately, the majority of people with cancer have tumors that are considered “cold” (those with few activated T cells or with other immune resistance mechanisms). For this group, PD-1 blockade benefits less than 5% of patients. Even across the hot and “warm” cancers, response rate to PD-1 blockade is less than 25%.

In the United States, approximately 1.8 million cases of cancer are diagnosed every year. And in 2018, there were an estimated 16,353,421 people in the United States living with cancer.

We’re turning up the heat on cancer